The stock's fall snapped a two-day winning streak.

Scotiabank upped their price objective on shares of Bio-Techne from $83.00 to $88.00 and gave the stock a “sector outperform” rating in a research report on Thursday, October 31st. Robert W.

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Bio-Techne TECH is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Find the latest BIO,TECHNE CDRN T1CH34.SA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

TECH Stock Likely to Gain From the Development Since the announcement on Dec. 10, Bio-Techne’s shares dipped 0.4%, closing at $76.81 in yesterday’s session. On a promising note, Bio-Techne ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...